Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01498484
Title Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Atara Biotherapeutics
Indications

Advanced Solid Tumor

nasopharynx carcinoma

lymphoma

leiomyosarcoma

Therapies

EB-VST cells

Age Groups: adult | child | senior
Covered Countries USA


No variant requirements are available.